

# THE BEST MARKER FOR DIAGNOSIS OF NET.

The Chromogranin A ELISA shows high specificity and sensitivity for different neuroendocrine tumors (NET) due to monoclonal antibodies directed against the central domain of molecule, which corresponds to the unprocessed central domain.


## **Chromogranin A origin and metabolism**

Chromogranin A (CgA) is thought to act as a pro-hormone. Its proteolysis is a key component of its physiology. This degradation releases different biologically active peptides (for example:

vasostatins, chromostatin, pancreastatin, parastatin), which possess different paracrine and autocrine functions. These peptides are not specific to NET-patients.

This proteolysis is tissue-specific and fragmentation of the protein is different, depending on its location. It primarily takes place in the cell, inside chromaffin granules. In immunohistochemistry, the presence of CgA in tumor cells is suggestive of a neuroendocrine origin of the tumor.

#### **Human CgA molecule sequence**



# Normal values measured with the Chromogranin A ELISA (30208352)

Circulating CgA exists in healthy subjects and the values obtained are independent of age and gender. Apparently healthy 101 subjects tested in the Chromogranin A ELISA showed serum values between 23 and 101 ng/mL, with a median of 56 ng/mL (95th percentiles).

# **Clinical importance**

Chromogranin A represents the best available biomarker<sup>1</sup> for diagnosis of neuroendocrine tumors (NETs) with clinical prognostic relevance, like for pheochromocytoma and carcinoids tumors.

The measurement of Chromogranin A is indicated as an aid in the diagnosis of patients with neuroendocrine tumors, e.g. gastroentero-pancreatic neuroendocrine tumors (GEP-NETs)<sup>2,3</sup>, in conjunction with clinical evaluation.

## **Chromogranin A ELISA**

The CE IVDD Chromogranin A ELISA (Ordering Number: 30208352) uses monoclonal antibodies that specifically recognize the central part of the molecule (Amino acids: 145-245), which corresponds to the unprocessed central domain. The kit measures intact and fragmented circulating CgA.

## This design is key for

- High specificity for NET patients
- Reliable and consistent results: standards based on human recombinant CgA
- High precision < 10% CV
- Excellent correlation to the gold Standard CgA RIA and other Random Access devices on the market

#### **PRODUCTS**

## 30208352

Chromogranin A ELISA

#### RELATED PRODUCTS

## **RE59395**

TriCat (Adrenalin, Noradrenalin, Dopamine) ELISA

#### RE59202


MetCombi Plasma ELISA

## RE59181

Metanephrine Urine ELISA

## RE59171

Normetanephrine Urine ELISA



## **Inter-Assay Precision**

Level	Number of Samples	Concentration ng/mL	%CV
1	34	81,6	6,43
2	36	122	4,68
3	31	182	4,13
4	35	407	3,19
5	36	445	3,98
6	35	632	4,73

## **Intra-Assay Precision**

Level	Number of Samples	Concentration ng/mL	%CV
1	28	51,3	11,5
2	28	187	6,4
3	28	442	6,8
4	20	697	7,0

# **Automation**

The Chromoganin A ELISA is semi-automated and will require general-purpose laboratory instruments. Furthermore, the assay can be easily automated on open ELISA systems like the Freedom Evolyzer®. However, the combined use of assays, process script and instrument has to be validated individually on site by each laboratory.

## References

- 1. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010 Sep;17(9):2427-43. doi: 10.1245/s10434-010-1006-3. Epub 2010 Mar 9. PMID: 20217257.
- 2. Ardill, Joy & Erikkson, B. (2004). The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocrine-related cancer. 10. 459-62. 10.1677/erc.0.0100459.
- 3. Bryan Oronsky, Patrick C. Ma, Daniel Morgensztern, Corey A. Carter, Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas, Neoplasia, Volume 19, Issue 12, 2017, Pages 991-1002, ISSN 1476-5586, https://doi.org/10.1016/j.neo.2017.09.002.

Supplied by:



Tel: +44 (0)1235 431390 sales@oxfordbiosystems.com www.oxfordbiosystems.com



Distributed by IBL International GmbH Flughafenstrasse 52a 22335 Hamburg

Germany

Phone: +49 (0)40-53 28 91-0 Fax: +49 (0)40-53 28 91-11 Email: IBL@Tecan.com www.tecan.com/ibl

Australia +61 3 9647 4100 Austria +43 62 46 89 330 Belgium +32 15 42 13 19 China +86 21 220 63 206 France +33 4 72 76 04 80 Germany +49 79 51 94 170 Italy +39 02 92 44 790 Japan +81 44 556 73 11 Netherlands +31 18 34 48 17 4 Nordic +46 8 750 39 40 Singapore +65 644 41 886 Spain +34 93 595 25 31 Switzerland +41 44 922 89 22 UK +44 118 9300 300 USA +1 919 361 5200 Other countries +41 44 922 81 11

Tecan Group Ltd. makes every effort to include accurate and up-to-date information within this publication, however, it is possible that omissions or errors might have occurred. Tecan Group Ltd. cannot, therefore, make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this publication. Changes in this publication can be made at any time without notice. All mentioned trademarks are protected by law. In general, the trademarks and designs referenced herein are trademarks, or registered trademarks, of Tecan Group Ltd., Männedorf, Switzerland. A complete list may be found at http://www.tecan.com/trademarks. Product names and company names that are not contained in the list but are noted herein may be the trademarks of their respective owners. For technical details and detailed procedures of the specifications provided in this document please contact your Tecan representative.

Tecan is in major countries a registered trademark of Tecan Group Ltd., Männedorf, Switzerland.

© 2025 Tecan Trading AG, Switzerland, all rights reserved.

www.tecan.com



FL 403228 V1.0 en, 2025